Pharma4ever Engineering ApS Financials, key figures and credit report
Gross profit 12 586.1 kDKK FY 2025 -11.5% vs 2024
EBIT 3 046.2 kDKK FY 2025 +100.8% vs 2024
Net debt -2 924.3 kDKK FY 2025 -200.6% vs 2024
Quick ratio 1.7 FY 2025 +0.6 vs 2024
Income statement (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | 1 056.29 | 3 834.94 | 14 792.80 | 14 219.64 | 12 586.11 |
| Employee benefit expenses | - 932.38 | -2 928.62 | -10 901.61 | -12 702.89 | -9 539.96 |
| EBIT | 123.91 | 906.33 | 3 891.19 | 1 516.75 | 3 046.16 |
| Other financial income | 0.12 | 2.84 | 4.43 | 0.95 | |
| Other financial expenses | -21.18 | -45.32 | -18.25 | - 184.95 | -65.59 |
| Pre-tax profit | 102.72 | 861.12 | 3 875.79 | 1 336.23 | 2 981.52 |
| Income taxes | -24.84 | - 190.56 | - 855.88 | - 298.40 | - 656.33 |
| Net earnings | 77.88 | 670.56 | 3 019.91 | 1 037.83 | 2 325.19 |
Assets (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Tangible assets total | |||||
| Investments total | |||||
| Long term receivables total | |||||
| Inventories total | |||||
| Current trade debtors | 78.13 | 2 339.90 | 5 157.88 | 6 294.89 | 2 652.71 |
| Current other receivables | 203.09 | 126.12 | 5.00 | ||
| Current deferred tax assets | 63.16 | 172.44 | 79.60 | ||
| Short term receivables total | 141.29 | 2 512.34 | 5 360.97 | 6 500.60 | 2 657.71 |
| Cash and bank deposits | 145.27 | 724.45 | 2 638.52 | 972.75 | 2 924.28 |
| Cash and cash equivalents | 145.27 | 724.45 | 2 638.52 | 972.75 | 2 924.28 |
| Balance sheet total (assets) | 286.56 | 3 236.79 | 7 999.49 | 7 473.35 | 5 581.99 |
Equity and liabilities (kDKK)
2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Share capital | 40.00 | 40.00 | 40.00 | 40.00 | 40.00 |
| Shares repurchased | 650.00 | 3 118.35 | 1 037.83 | 2 325.19 | |
| Retained earnings | - 572.12 | -3 019.91 | -1 037.83 | -2 325.19 | |
| Profit of the financial year | 77.88 | 670.56 | 3 019.91 | 1 037.83 | 2 325.19 |
| Shareholders equity total | 117.88 | 788.44 | 3 158.35 | 1 077.83 | 2 365.19 |
| Non-current liabilities total | |||||
| Current trade creditors | 86.30 | 30.45 | 1 674.40 | 1 307.67 | 1 146.92 |
| Current owed to participating | 742.66 | ||||
| Short-term deferred tax liabilities | 60.88 | 478.33 | |||
| Other non-interest bearing current liabilities | 82.37 | 1 675.24 | 3 105.86 | 5 087.85 | 1 591.55 |
| Current liabilities total | 168.67 | 2 448.35 | 4 841.14 | 6 395.52 | 3 216.80 |
| Balance sheet total (liabilities) | 286.56 | 3 236.79 | 7 999.49 | 7 473.35 | 5 581.99 |
Secure checkout
Buy AI Credit Risk Report
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
How it works
- 01 You pay €3 (incl. VAT) securely by card via Stripe.
- 02 You enter your email address in Stripe's payment window – the report is sent there.
- 03 The report is generated automatically and sent as a PDF within 30 minutes.
- 04 If generation should fail, you are not charged.
- 05 You receive the receipt by email once the report has been generated and completed.
Do you want to buy the AI Credit Risk Report (3 EUR / report)?
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.
Page generated